MX391017B - Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas. - Google Patents
Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.Info
- Publication number
- MX391017B MX391017B MX2017002852A MX2017002852A MX391017B MX 391017 B MX391017 B MX 391017B MX 2017002852 A MX2017002852 A MX 2017002852A MX 2017002852 A MX2017002852 A MX 2017002852A MX 391017 B MX391017 B MX 391017B
- Authority
- MX
- Mexico
- Prior art keywords
- conditions
- lymphocytes
- infiltrate
- activation
- mils
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title abstract 2
- 206010021143 Hypoxia Diseases 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 230000001146 hypoxic effect Effects 0.000 title 1
- 239000013255 MILs Substances 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0669—Bone marrow stromal cells; Whole bone marrow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045782P | 2014-09-04 | 2014-09-04 | |
| US201562186040P | 2015-06-29 | 2015-06-29 | |
| PCT/US2015/048536 WO2016037054A1 (en) | 2014-09-04 | 2015-09-04 | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017002852A MX2017002852A (es) | 2017-05-30 |
| MX391017B true MX391017B (es) | 2025-03-21 |
Family
ID=55440392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002852A MX391017B (es) | 2014-09-04 | 2015-09-04 | Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas. |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US9687510B2 (enExample) |
| EP (2) | EP3188740B1 (enExample) |
| JP (2) | JP6865160B2 (enExample) |
| KR (1) | KR20170067751A (enExample) |
| CN (1) | CN107109364A (enExample) |
| AU (2) | AU2015311761B2 (enExample) |
| CA (1) | CA2959994C (enExample) |
| DK (1) | DK3188740T3 (enExample) |
| ES (1) | ES2877108T3 (enExample) |
| IL (2) | IL250746B (enExample) |
| MX (1) | MX391017B (enExample) |
| PT (1) | PT3188740T (enExample) |
| WO (1) | WO2016037054A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| WO2016037054A1 (en) | 2014-09-04 | 2016-03-10 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| JP2018520679A (ja) | 2015-06-29 | 2018-08-02 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 免疫チェックポイントキメラ抗原受容体療法 |
| WO2017008019A1 (en) * | 2015-07-08 | 2017-01-12 | The Johns Hopkins University | Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy |
| HUE066460T2 (hu) | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| KR102618948B1 (ko) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법 |
| AU2017382243A1 (en) * | 2016-12-22 | 2019-05-02 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| JP2021516666A (ja) * | 2018-03-22 | 2021-07-08 | ウィンドミル セラピューティクス インコーポレイテッド | 前立腺がん特異的髄浸潤リンパ球およびその使用 |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US12611427B2 (en) | 2018-11-05 | 2026-04-28 | Iovance Biotherapeutics, Inc. | Treatment of NSCLC patients refractory for anti-PD-1 antibody |
| US20210338730A1 (en) * | 2018-11-05 | 2021-11-04 | Windmil Therapeutics, Inc. | Marrow Infiltrating Lymphocytes With Increased Clonality and Uses Thereof |
| MY210603A (en) | 2018-11-05 | 2025-10-01 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| MX2021006399A (es) * | 2018-11-30 | 2021-07-15 | Windmil Therapeutics Inc | Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia. |
| CN114072158A (zh) * | 2019-03-22 | 2022-02-18 | 温德弥尔治疗公司 | 肺癌特异性骨髓浸润淋巴细胞及其用途 |
| US20230100744A1 (en) * | 2020-02-28 | 2023-03-30 | Windmil Therapeutics, Inc. | Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils |
| WO2022066872A1 (en) * | 2020-09-24 | 2022-03-31 | Windmil Therapeutics, Inc. | Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
| WO2025160242A1 (en) * | 2024-01-23 | 2025-07-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of generating tils from cerebro spinal fluid for leptomeningeal disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3243600A (en) | 1999-02-23 | 2000-09-14 | Kathleen S. Carswell | Improved method of culturing t cells |
| US6811788B2 (en) * | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| EP2111231A4 (en) * | 2007-02-13 | 2010-12-15 | Univ Northeastern | METHOD AND COMPOSITIONS FOR IMPROVING IMMUNE REACTIONS |
| WO2014085437A2 (en) * | 2012-11-27 | 2014-06-05 | The Johns Hopkins University | Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity |
| EP2364152A4 (en) * | 2008-11-03 | 2013-02-13 | Univ Johns Hopkins | METHOD FOR PRODUCING AND USING MARKINFILTRATING LYMPHOCYTES (MILS) |
| BR112014007947A2 (pt) * | 2011-10-03 | 2017-04-18 | Univ Los Andes | método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5 |
| EP2804625A4 (en) | 2012-01-17 | 2015-10-28 | Univ Northeastern | METHOD AND COMPOSITIONS FOR THE EXPANSION OF IMMUNOSUPPRESSIVE REGULATORY T CELLS IN VITRO AND USES THEREOF |
| JP2014090678A (ja) * | 2012-11-01 | 2014-05-19 | Ito En Ltd | 容器詰野菜汁及び／又は果汁含有飲料及びその製造方法、並びに容器詰野菜汁及び／又は果汁含有飲料の呈味劣化防止方法 |
| WO2016037054A1 (en) | 2014-09-04 | 2016-03-10 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| AU2017382243A1 (en) * | 2016-12-22 | 2019-05-02 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| JP2021516666A (ja) * | 2018-03-22 | 2021-07-08 | ウィンドミル セラピューティクス インコーポレイテッド | 前立腺がん特異的髄浸潤リンパ球およびその使用 |
| MX2021006399A (es) * | 2018-11-30 | 2021-07-15 | Windmil Therapeutics Inc | Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia. |
-
2015
- 2015-09-04 WO PCT/US2015/048536 patent/WO2016037054A1/en not_active Ceased
- 2015-09-04 EP EP15838358.8A patent/EP3188740B1/en active Active
- 2015-09-04 KR KR1020177009084A patent/KR20170067751A/ko not_active Abandoned
- 2015-09-04 DK DK15838358.8T patent/DK3188740T3/da active
- 2015-09-04 JP JP2017512293A patent/JP6865160B2/ja not_active Expired - Fee Related
- 2015-09-04 US US15/112,353 patent/US9687510B2/en active Active
- 2015-09-04 PT PT158383588T patent/PT3188740T/pt unknown
- 2015-09-04 CN CN201580059448.3A patent/CN107109364A/zh active Pending
- 2015-09-04 CA CA2959994A patent/CA2959994C/en active Active
- 2015-09-04 ES ES15838358T patent/ES2877108T3/es active Active
- 2015-09-04 EP EP21167891.7A patent/EP3922254A1/en not_active Withdrawn
- 2015-09-04 MX MX2017002852A patent/MX391017B/es unknown
- 2015-09-04 AU AU2015311761A patent/AU2015311761B2/en not_active Ceased
-
2017
- 2017-02-23 IL IL250746A patent/IL250746B/en active IP Right Grant
- 2017-05-26 US US15/606,766 patent/US10406178B2/en active Active
- 2017-05-26 US US15/606,951 patent/US10172887B2/en active Active
-
2018
- 2018-12-03 US US16/207,864 patent/US11160830B2/en not_active Expired - Fee Related
-
2019
- 2019-07-30 US US16/526,656 patent/US11406666B2/en active Active
-
2020
- 2020-07-28 IL IL276347A patent/IL276347B/en unknown
-
2021
- 2021-02-02 AU AU2021200648A patent/AU2021200648A1/en not_active Abandoned
- 2021-04-05 JP JP2021063957A patent/JP7197213B2/ja active Active
- 2021-09-30 US US17/490,691 patent/US20220016172A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/864,546 patent/US20230000919A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391017B (es) | Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas. | |
| JOP20200016B1 (ar) | أجسام مضادة لـ cd137 | |
| PH12017501748B1 (en) | Antibodies to icos | |
| PH12016500137A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
| MX2020006668A (es) | Anticuerpos para lilrb2. | |
| MY199019A (en) | Pd-1 antibodies | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
| BR112017020952A2 (pt) | método de tratamento de câncer, composição e uso da composição | |
| MX379270B (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2021002900A (es) | Composicion con complejos de nanoparticulas/anticuerpos de paclitaxel unidos a albumina para usarse al tratar linfoma. | |
| MX2016016617A (es) | Tratamiento de mielomas. | |
| MX2020010375A (es) | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX381278B (es) | Composición para la estimulación ovárica controlada. | |
| NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
| MX2015009818A (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple. | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth | |
| MX2016001104A (es) | Composiciones para tratar engrosamiento de la piel. | |
| EA201591709A1 (ru) | 5-бром-индирубины | |
| EP4541423A3 (en) | Dosing regimen of avelumab for the treatment of cancer | |
| MX2016010229A (es) | Conjugados del factor vii. | |
| PH12017501897A1 (en) | 2-thiopyrimidinones | |
| GB201105129D0 (en) | Compositions and methods for treating, diagnosing and monitoring disease |